Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female,between 35 and 85 years of age~2. Indicated for Total hip replacement for various hip diseases~3. Has preoperative DXA study within 3 months before the total hip replacement procedure or willing to receive preoperative DXA study as a baseline comparison~4. Signed written informed consent~5. Standard transgluteal approach for total hip replacement using Zimmer Triology Cup and Versys Fiber Metal Taper Stem with metal to highly cross-linked polyethylene bearing surface~Exclusion Criteria:~1. Any prior use of intravenous bisphosphonate within the last 2 years~2. Uncontrolled seizure disorders associated with falls~3. A history of invasive malignancy of any organ system, treated or untreated, within the past five years; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed~4. Carcinoma in situ of the uterine cervix~5. History of osteogenesis imperfecta, multiple myeloma, or Paget's disease~6. Active primary hyperparathyroidism~7. History of iritis or uveitis~8. Self-reported history of diabetic nephropathy or retinopathy~9. AST or ALT more than twice the upper limit of normal~10. Alkaline phosphatase more than twice the upper limit of normal~11. Serum calcium 2.75 mmol/L (11.0 mg/dL)~12. Baseline renal insufficiency (calculated creatinine clearance 35 ml/min)~13. History of hypersensitivity to bisphosphonates~14. Use of any investigational drug(s) and/or devices within 30 days prior to randomization~15. Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the participant from adhering to the Protocol or completing the trial per protocol~16. Use of hip protectors~17. With implant or prosthesis on the contralateral hip joint

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aclasta (Type: EXPERIMENTAL): Aclasta IV once annual for 2 years
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group

Based on this trial design, predict the completion outcome and termination type (if applicable).